PROGRESS REPORT 2012 - CLARA

 
PROGRESS REPORT 2012 - CLARA
PROGRESS
REPORT
2012
PROGRESS REPORT 2012 - CLARA
Contents

             EDITORIAL                                                                                                                                        3

             CLARA’S MISSIONS                                                                                                                                 4

             KEY FIGURES 2012                                                                                                                                 5

             STRUCTURING OF RESEARCH                                                                                                                          6
             > Scientific Animation ....................................................................................................................... 6
               UÊ /œÜ>À`ÃÊ,iÃi>ÀV Ê«>À̘iÀà ˆ«ÃÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 6
               UÊ ˜Êˆ˜ŽÊÜˆÌ ÊÌ iʈ˜`ÕÃÌÀÞÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 8
             > Emerging Axes............................................................................................................................. 10
               UÊ Փ>˜]ÊiVœ˜œ“ˆVÊ>˜`ÊÜVˆ>ÊÃVˆi˜Við°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 10
               UÊ ˜ÛˆÀœ˜“i˜Ì]Ê ÕÌÀˆÌˆœ˜Ê>˜`Ê >˜ViÀÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 12
             > Transverse actionsÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 14
             > International influence ................................................................................................................. 16

             SUPPORTING RESEARCH PROJECTS                                                                                                                  18
             > Fostering the Emergence of Projects ........................................................................................... 18
               UÊ œLˆˆÌÞÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° 18
               UÊ "˜Vœ-Ì>ÀÌiÀ .............................................................................................................................. 19
             > CLARA Proof of Concept: Industrial and clinical transfer ................................................................ 20
             > Major interregional projects ......................................................................................................... 22
             > Financing of interregional projects ............................................................................................... 24

             FINANCIAL RESULTS                                                                                                                             26

             APPENDIX                                                                                                                                      27
             > Financing attributed in 2012 ....................................................................................................... 28
             > Financial Tables ............................................................................................................................ 37

             CLARA’S COORDINATION TEAM                                                                                                                     43

    More info on www.canceropole-clara.com

2
PROGRESS REPORT 2012 - CLARA
Editorial

2012, A NEW
MOMENTUM FOR THE
CANCÉROPÔLE LYON
AUVERGNE RHÔNE-ALPES

As a leading research cluster in supporting the
creation and advancement of large-scale projects in
oncology, the Cancéropôle Lyon Auvergne Rhône-
Alpes (CLARA), has strengthened its commitment,
all through 2012, to the members of its network,
at the institutional level and by the deployment of
its programs.

As CLARA reaches its 10th anniversary and a new        Sciences, Environment, Nutrition) by helping them
Cancer Plan is on the horizon, the CLARA executive     build strong scientific foundations and tackle the
leadership sought to breathe new energy into the       new challenges in the fight against Cancer.
organization and offer fresh perspectives. In an
economic climate requiring that every outlay proves    For 2013, CLARA’s path is clear and has four
as cost effective as possible, CLARA had to solidify   objectives:
its position to ensure that researchers, clinicians,
and industry professionals in Oncology have the        s Transform CLARA into a “Network of Networks
best chance of success and that patients receive         in Oncology” to foster dialogue between all
the finest care.                                          stakeholders

Therefore, an Executive Steering Committee was         s Offer an interregional scientific strategy that
formed in 2012 to assist CLARA in moving toward          integrates basic and clinical research
a “Network of Networks in Oncology”, enhancing
CLARA’s capacity to bring together all the             s Address the issue of inequity in our approaches
stakeholders in Clermont-Ferrand, Saint-Étienne,         to Cancer by fleshing out the emerging themes
Grenoble and Lyon.                                       in Oncology that are now at the center of patient
                                                         lives and cause for societal concern
The year 2012 also saw the development of official
ties with the competitiveness cluster Lyonbiopôle.     s Develop closer ties with Lyonbiopôle to improve
The objective is twofold: converge the two               the regional innovation ecosystem.
clusters’ methods of fostering the emergence of
innovation and accrediting R&D projects as well as     Working together will get us farther down the road
assist in achieving optimal knowledge transfer and     to Cancer Research.
exploitation of research results to create clinical
applications.

Given the historic missions of CLARA to lead and
organize Oncology Research, it is now taking a         Véronique TRILLET-LENOIR         Amaury MARTIN
major step forward in broadening its support of        *ÀiÈ`i˜Ì]Ê                      -iVÀiÌ>ÀÞÊi˜iÀ>
emerging themes (Human, Economic and Social            >˜>}i“i˜ÌÊ œ““ˆÌÌii

                                                                                              Progress
                                                                                              P  g es Report 2012
                                                                                                             20 2

                                                                                                                    3
PROGRESS REPORT 2012 - CLARA
CLARA’s Missions

          A NETWORK OF NETWORKS
          FOR ADVANCING CANCER RESEARCH

          Since its creation in 2003 as part of the first Cancer    CLARA’S GOALS
          Plan, the Cancéropôle Lyon Auvergne Rhône-Alpes
          (CLARA) has been uniting and leading a network          > Consolidate a network of experts
          associating academic, clinical and industrial             to accelerate Cancer Research
          strengths in Cancer Research in Rhône-Alpes
          Auvergne.                                               > Support the clinical development
                                                                    of innovative projects
          Mandated to organize Oncology Research, CLARA
                                                                  > Reinforce national and international
          is one of the key stakeholders involved in innovative
          projects that focus on the quick exploitation of          collaborative dynamics to increase the
          research results for the direct benefit of patients.       participation of research teams in ambitious
                                                                    programs
          Supported by the French National Cancer Institute       > Fully engage in global Cancer efforts
          (INCa) and 14 local authorities, CLARA is working         by partnering with Lyonbiopôle with the
          to promote interregional strengths on the national        support of local authorities
          and international stages and contribute to economic
          growth in the Rhône-Alpes and Auvergne regions.         > Speed up the creation of companies, their
                                                                    growth, and their interregional establishment

          CLARA: Network of Networks in Oncology in Rhône-Alpes and Auvergne

                                                                    LYON
                                                                    IARC, CRMN, CRCL, ENS,
                                                                    HCL, CLB, SIRIC, EMRC, CTD,
                                                                    RRC Réseau Espace Santé
                                                                    Cancer Rhône-Alpes, UCBL,
                                                                    LYONBIOPÔLE, SYNERGIE
                                                                    LYON CANCER, PARRC-ARA,
                                                                    CALYM, ELI, WSN, GCS-LCU
                    CLERMONT-FERRAND
                    CHU, CJP, RRC
                    ONCAUVERGNE, UA…

                                             SAINT-ÉTIENNE
                                             CHU, ICL, HYGÉE,                         GRENOBLE
                                             EMRC, EMSE…                              IAB, GIN, CHU, CEA,
                                                                                      ESRF, EMRC, UJF,
                                                                                      UPMF, MINALOGIC,
                                                                                      ETOILE, GIRC…

    More info on www.canceropole-clara.com

4
PROGRESS REPORT 2012 - CLARA
Key Figures 2012

CANCER RESEARCH IN
RHÔNE-ALPES AND
AUVERGNE

>   M18         received by research teams for
    130 projects*

>   1500 active researchers**
> Second region in France in the publication
    of scientific papers
    s 15% of French publications in Oncology
       (Ile-de-France 36%)**
    s 20% of leading publications (Top 1%)
      (Ile-de-France 45%)**                                             CANCÉROPÔLE LYON
    s 17% of high-profile publications (Top 10%)
      (Ile-de-France 37%)**                                             AUVERGNE RHÔNE-ALPES
> A network of top researchers with
    outstanding results after the INCa 2012 call
    for projects, especially in clinical research                       > Reinforced influence
    and emerging themes                                                  s 1500 people involved in 31 scientific events
    s 23% of projects in the Clinical Cancer                             s 79 press releases***
      Research Hospital Program (PHRC)                                  > Increased support for emerging innovation
    s 20% of projects in Human and Social                                in 2012
      Sciences, Epidemiology and Public Health                           s 425,000 allocated by CLARA to 18 projects*
    s 20% of projects in Intervention Research and                       s 10 OncoStarter* projects to ensure
      Reduction of Social Inequalities                                     sustained project development
                                                                         s 8 mobility grants* to help young researchers
IÊ-iiÊ`iÌ>ˆÃʜ˜Ê«ÀœiVÌÃʈ˜ÊÌ iÊ>««i˜`ˆÝÊ
IIÊ-œÕÀViÃ\Ê/ œ“Ãœ˜Ê,iÕÌiÀÃÊ7œ-Ê­>˜Õ>ÀÞÊÓä£Ó®ÆÊ ˆLˆœ“iÌÀˆVÊ           > Proof of Concept program since 2007
˜>ÞÈÃʜvÊ >˜ViÀÊ,iÃi>ÀV \ÊÊ >̈œ˜>Ê˜ÌiÀ‡ >˜VjÀœ«žiÉ >Ê-ÌÕ`ÞÊ
­ՏÞÊÓä£Ó®Ê­º>V̈Ûi»ÊÀiviÀÃÊ̜Ê>ÕÌ œÀʜÀÊVœ>ÕÌ œÀʜvÊ>Ìʏi>ÃÌÊÌ ÀiiÊ    s 32 projects supported, 15* in progress and
«ÕLˆV>̈œ˜ÃÊLiÌÜii˜ÊÓääÈÊ>˜`ÊÓ䣣®                                        5 in post-closure follow-up
IIIÊ-œÕÀVi\Ê*ÀiÃÃʘ`iÝÊ­«Àˆ˜Ìʓi`ˆ>ʜ˜Þ®                               s 25,1M invested by interregional business
                                                                           partners
                                                                         s 12,2M allocated by local authorities and the
                                                                           European Regional Development Fund (ERDF)

                                                                        > Concrete results
                                                                         s 1 robotic surgical device on the market
                                                                         s 5 clinical development projects
                                                                         s 6 preclinical assessments performed

                                                                                                            Progress
                                                                                                            P  g es Report 2012
                                                                                                                           20 2

                                                                                                                                  5
PROGRESS REPORT 2012 - CLARA
Structuring of Research

          SCIENTIFIC ANIMATION

          SCIENTIFIC ANIMATION: AT THE HEART OF CLARA’S
          ACTIONS TO CREATE SYNERGIES AND PROMOTE
          RESEARCH PARTNERSHIPS

          Scientific animation is a top priority for CLARA and
          part of an overall strategy of supporting activities
                                                                                 KEY FIGURES 2012
          in key themes and stimulating the development
          of partnerships between network members and
          beyond.                                                                > 16 events
                                                                                 > €400,000 annual budget
          The events organized or supported in 2012
          have made it possible to reinforce interregional                       > €30,000 allocated to 9 events
          interaction, thus enriching the research landscape                     > 1500 people mobilized
          with new projects, new innovations, and many
          thematic collaborations.

          As a network leader that knows how to mobilize
          interregional expertise and assets, CLARA has
          directly supported several events. Selected
          according to their alignment with the Cancer Plan                    SPOTLIGHT ON…
          priorities, these events offer opportunities for the
                                                                               7TH SCIENTIFIC FORUM
          network to build better targeted relationships and
          promote scientific culture.
                                                                               The flagship CLARA event, the 2012 edition offered:
                                                                               s Theme day on innovative approaches to combating
                                                                                 Cancer with monoclonal antibodies (partnership
                                                                                 with Lyonbiopôle)
                                                                               s All-day meeting of interregional actors in Cancer
                                                                                 Research, allowing them to present their ongoing
                                                                                 works and discuss the most recent advances
                                                                                 in basic, clinical and translational research in
                                                                                 thematic sessions, in partnership with national
                                                                                 and international organizations
                                                                               s Satellite event on Nanomedicine and Oncology
                                                                                 in Rhône-Alpes Auvergne and Catalonia (in
                                                                                 partnership with the Biocat cluster)
                                                                               Internationally renowned speakers came together
                                                                               to bring the theme beyond interregional borders
                                                                               (20% of participants from outside the interregional
                                                                               area) and allow the development of partnerships in
                                                                               the study of monoclonal antibodies.
          >˜ˆViÊ,   ,/]Ê i˜ÌiÀÊvœÀÊÌ iÊ-ÌÕ`ÞʜvÊ ÀÕ}Ê iÛiœ«“i˜Ì]Ê
          /ÕvÌÃÊ1˜ˆÛiÀÈÌÞ]ʈ˜ÛˆÌi`Êëi>ŽiÀʜvÊÌ iÊÇÌ Ê ,Ê-Vˆi˜ÌˆwVÊœÀՓ

    More info on www.canceropole-clara.com

6
PROGRESS REPORT 2012 - CLARA
HIGHLIGHTS 2012
 January                                                             June
 s Open meeting on Nanotechnologies,                                 s Cancer Cells On-Chips: Now and the Future,
   Imaging and Cancer - Presentation of projects                       Lyon y
   and networking                                                    s Association des Neuro-Oncologues
 February                                                              d’Expression Française (ANOCEF), [French
 s Inter-Cancéropôles conference ˆœL>Ã̜“>\ÊÊ                       association for neuro-oncology and gene
   œiVՏ>ÀÊ>˜`Ê iÕ>ÀÊ >À>VÌiÀˆâ>̈œ˜Ê>˜`Ê                         expression], Clermont-Ferrand y
   *ÀiVˆ˜ˆV>Êœ`iÃ] Marseille                                     s 8th Annual Forum of the French Sarcoma
 March                                                                 Group – Bone Tumor Study Group, Lyon y
 s 7th CLARA Scientific Forum, Lyon                                   September
 s 30th meeting of the Club for the Study                            s 5th Inter-Cancéropôles Bioinformatics
   of Epithelial Cells of the Digestive Tract                          Workshop, Lyon
   (CECED), Grenoble y
                                                                     October
 April                                                                s 2nd Translational Research Meeting,
 s 4th Inter-Cancéropôles Workshop on                                   Gerland Lyon-Sud y
   Bioinformatics, Nice
                                                                     November
 May                                                                 s 12th International Conference on Cancer-
 s Workshop on iœ}À>« ˆV>Ê««Àœ>V iÃÊÌœÊ                             Induced Bone Disease, Lyon y
    Û>Õ>̈˜}Ê Ý«œÃÕÀiÊ̜Ê*iÃ̈Vˆ`iÃ, Lyonc
 s 6th Francophone Conference on Clinical                            s 2nd Franco-Chinese Symposium on
   Epidemiology (EPICLIN) / 19th Statistician                          Oncology Research, Lyon
   Forum of the Centers for the Fight Against                        December
   Cancer, Lyon y                                                    s 11th LOWRAD International Conference,
 s 3rd edition of Courir Pour Elles, (Women’s                          Lyon y
   Run Against Breast Cancer), Lyon/Domaine de
   Lacroix Lavalc

  "À}>˜ˆâiÀʜÀÊVœ‡œÀ}>˜ˆâiÀÊ              y ՘`ˆ˜}              c˜Ã̈ÌṎœ˜>Ê«>À̘iÀ

CLARA’S MISSIONS

         Cancerology Community
      Reseachers, Industrials, Clinicians...            Research Projects in Cancerology

                                Research
                                support                                                            > Scientific
                                                                                                     and Therapeutic
                                                                              Financing              Innovations
                                                                                                     for Patients
    Interregional
                                                                                                   > Territorial
     Community                                         Expertise
     Animation                                                                                       Economic
                                                      and Projects                                   Development
                                                       Follow-up

                                                                                                         Progress Report 2012

                                                                                                                                7
PROGRESS REPORT 2012 - CLARA
Structuring of Research

          SCIENTIFIC ANIMATION

          SCIENTIFIC ANIMATION RELATED TO DEVELOPMENT:
          PROMOTING THE TRANSFER OF RESEARCH RESULTS
          TO INDUSTRY AND HEALTHCARE

                                                                             Entrusted by local authorities to play a key role in
             HIGHLIGHTS 2012                                                 stimulating economic growth, CLARA organized
                                                                             several scientific events in 2012 related to the
             April                                                           exploitation of research results in order to promote
             s Webinar ˜œÜi`}iÊ/À>˜ÃviÀÊ>˜`Ê Ý«œˆÌ>̈œ˜ÊœvÊ               the transfer of results to industry and patient care.
               ,iÃi>ÀV Ê,iÃՏÌÃʈ˜Ê"˜Vœœ}Þ\Ê1˜`iÀÃÌ>˜`ˆ˜}ÊÌ iÊ
                ,Ê*ÀœœvʜvÊ œ˜Vi«Ì                                        Whether in the form of webinars, training sessions,
             July                                                            workshops or meetings, the objective is to expand
             s Workshop on Industrial Property and                           the expertise of the network and help build
               Innovation Strategy (Part 1), Lyon *                          partnerships between industry and academics.
             September
             s Webinar ,>ÀiÊ >˜ViÀÃÊ>ÃÊœ`iÃÊvœÀÊ ˆ˜ˆV>Ê
               *ÀœœvʜvÊ œ˜Vi«ÌÊvœÀʘ˜œÛ>̈ÛiÊ >˜ViÀÊ
               /Ài>̓i˜ÌÃ
             s Educational Session of the CLARA
               Regulatory Unit >˜ViÀÊ6>VVˆ˜iÃ] Lyon
             s Workshop on Industrial Property and
               Innovation Strategy (Part 2), Lyon *
             October
             s Education: CLARA-MATWIN Proof of
               Concept Training ˜ÌÀœ`ÕV̈œ˜ÊÌœÊ ÀÕ}Ê
                 ˆÃVœÛiÀÞ\ÊÀœ“ÊÌ iÊ>LÊÌœÊ >ÀÞÊ ˆ˜ˆV>Ê1Ãi,
               Lyon
             s Workshop on Industrial Property and
               Standards]ÊLyon *
             November
             s Workshop on Protecting Combination
               Products in Healthcare: ˆœÌiV ˜œœ}ÞÊ
                                                                             SPOTLIGHT ON…
               ˜Ûi˜Ìˆœ˜ÃÊqÊi`ˆV>Ê iۈViÃ] Lyon *                          TRAINING SESSION INTRODUCTION
             December                                                        TO DRUG DISCOVERY: FROM THE
             s Workshop on Technology Forecasting and                        LAB TO EARLY CLINICAL CARE, LYON
               Competitive Intelligence in R&D Projects]
               Lyon *
             s 5th CLARA Industrial/Academic Encounters]                     Organized by CLARA and MATWIN SAS, this
               Lyon                                                          training day was specifically addressed to ,Ê
                                                                             *ÀœœvÊ œvÊ œ˜Vi«Ì and /7 2012 project leaders.
               "À}>˜ˆâiÀʜÀÊVœ‡œÀ}>˜ˆâiÀ
             * *>ÀÌʜvÊÌ iʈ˜`ÕÃÌÀˆ>Ê«Àœ«iÀÌÞÊ>Ü>Ài˜iÃÃÊ«Àœ}À>“ÊÃiÌÊÕ«Ê     Intended to meet the needs of academic researchers
               LÞÊÌ iÊÀi˜V Ê >̈œ˜>Ê˜`ÕÃÌÀÞÊ*Àœ«iÀÌÞʘÃ̈ÌÕÌiÊ­ *®]Ê   who want to pursue their work continuously until
               ޜ˜Lˆœ«ži]ʇ >ÀiÊ ÕÃÌiÀÊ>˜`Ê ,Ê­ÃiiÊëœÌˆ} Ìʜ˜Ê
               «>}iʙ®                                                       proof of concept and beyond until transfer to
                                                                             industry and clinical care, the purpose of this two-
                                                                             session training program was to raise awareness
                                                                             of the specific issues and challenges inherent in
                                                                             development.

    More info on www.canceropole-clara.com

8
PROGRESS REPORT 2012 - CLARA
SPOTLIGHT ON…
  KEY FIGURES 2012                                     WORKSHOPS ON INDUSTRIAL
                                                       PROPERTY AWARENESS
  > 10 events related to technology
    transfer                                           First launched in 2008, CLARA partnered in 2012
  > €36,000 annual budget dedicated to                 with the French National Industry Property Institute
    events related to technology transfer              (INPI), Lyonbiopôle and I-Care Cluster to organize
                                                       workshops on industrial property awareness.
  > 400 people mobilized
                                                       These workshops are means for any economic
                                                       and Research actors concerned with protecting
SPOTLIGHT ON…                                          industrial innovation as a differentiating factor in
5TH CLARA INDUSTRIAL/ACADEMIC                          competitiveness and growth.
ENCOUNTERS
This key annual event brings together actors in
Oncology Research and development in Rhône-               THEY TALKED ABOUT IT…
Alpes and Auvergne. In 2012, the CLARA Industrial/
Academic Encounters offered opportunities for             Encounter with Gabriele BARABINO, Jean-
face-to-face meetings between established and             Marc PHELIP and Michèle COTTIER, ,Ê
potential partners (like a business convention) as        /Àœ« ˆiÃÊÓä£Ó
well as a plenary session on the complementary
strengths of engineering sciences and Oncology,           º ,Ê ˆÃÊ >Ê ÃÌÀœ˜}Ê ii“i˜ÌÊ œvÊ
underscoring technological and clinical challenges        “œÌˆÛ>̈œ˜Ê >˜`Ê ÃÌÀÕVÌÕÀˆ˜}Ê ÜˆÌ ˆ˜Ê œÕÀÊ
and opportunities.                                        Ìi>“Ê >˜`Ê «ÀœiVÌÃÊ >˜`Ê ˆÃÊ ˆ“«œÀÌ>˜ÌÊ ˆ˜Ê
Special focus was given to the high potential             Vœ˜˜iV̈˜}ÊÕÃÊ̜ÊÌ iʜÕÌÈ`iÊܜÀ`°
for innovation through a combined approach                 iÈ`iÃÊ œÕÀÊ ÀiëiV̈ÛiÊ >V̈ۈ̈iÃ]Ê
encompassing engineering and Cancer Research.               ,Ê ˆÃÊ Ì iÊ “œÌ iÀ œÕÃiÊ œvÊ œÕÀÊ
Participants learned of the conclusions reached by a         " "" Ê«ÀœiVÌ°»
joint CLARA and I-Care Cluster scientific committee
which organized discussions throughout the year
among representatives from medicine, research
and business.
During this event, two high-potential projects
received the CLARA 2012 Trophies:
s Development of Functional Fluorescent
  Nanoparticles for Detecting Colorectal
  Tumors (G. BARABINO and J.-M. PHELIP,
  LINA EA 462 Laboratory / Jean Monnet University,
  CHU Saint-Étienne)                                      ˆV miÊ "// ,]Êi>˜‡>ÀVÊ* *]Ê>˜`Ê>}>ˆÊ6" ]Ê
                                                           ,Ê/Àœ« ˆiÃÊÓä£Ó
s Transthoracic Therapeutic Imaging Using 3-D
  Magnetic Resonance Imaging-Ultrasound                  Read their complete comments on…
  Hybrid Guidance (M. VIALLON, P. CROISILLE              www.canceropole-clara.com
  and S. SALOMIR, CREATIS, University Hospitals
  of Geneva)

                                                       / iÊ ,Ê Ìi>“Ê Ì >˜ŽÃÊ >Ê Ì iÊ «>À̈Vˆ«>˜ÌÃÊ ˆ˜Ê Ì iÊ ÃÌÕ`ÞÊ
                                                       }ÀœÕ«ÃÊ >ÃÊ ÜiÊ >ÃÊ Ì iÊ iÝ«iÀÌÃÊ Ü œÊ >ÌÌi˜`i`Ê Ì iÊ iÛi˜ÌÃ]Ê
                                                       “œÃÌʘœÌ>LÞÊi>˜‡>VµÕiÃÊ<  ,Ê>˜`Ê>VµÕiÃÊ - "/ -°

                                                                                                       Progress Report 2012

                                                                                                                              9
PROGRESS REPORT 2012 - CLARA
Structuring of Research

           EMERGING THEMES

           HUMAN, ECONOMIC AND SOCIAL SCIENCES IN
           ONCOLOGY: PUTTING PATIENTS AT THE HEART
           OF RESEARCH

           Recognizing the importance of the human, economic
           and social sciences in basic and clinical research,
                                                                     KEY FIGURES 2012
           CLARA supported the expansion of the working
           group in 2012 in order to welcome new actors.             > 1st French Cancéropôle in Social
           To achieve regional and national visibility, several        Sciences related to Oncology**
           high-priority themes were selected regarding:             > 90 researchers**
           s Prevention                 s Healthcare                 > 20 research teams*
           s Social inequalities          management
                                                                     > 15 laboratories evaluated by
           s Doctor-patient             s Technological                AERES, including 9 rated A+ and A*
             relationship                 developments
                                        s Epidemiological            > 3 OncoStarter projects launched
                                          indicators                   in 2012
           At the crossroads of the issues of personal risk,         > 20% of projects funded by INCa
           lifestyle and environmental and community risks             in the Human and Social Sciences,
           for the individual, the Human, Economic and Social          Epidemiology and Public Health are
           Sciences focus area of CLARA can spearhead or               CLARA projects
           advance Research involving basic and applied
           disciplines.                                              I՘iÊ Óä£Ó\Ê "ÛiÀۈiÜÊ œvÊ Ì iÊ ˆ˜ÌiÀÀi}ˆœ˜>Ê `ÀˆÛˆ˜}Ê vœÀViÃÊ ˆ˜Ê
                                                                     , ž˜i‡«iÃÊ ÕÛiÀ}˜iÊ ˆ˜Ê Փ>˜Ê >˜`Ê ÃœVˆ>Ê ÃVˆi˜ViÃ]Ê Õ˜`iÀÊ
                                                                     Ì iÊÃÕ«iÀۈȜ˜ÊœvÊ°Ê 8" Ê­ ,ʈ˜ÌiÀ˜>Ê`>Ì>®
                                                                     II>˜Õ>ÀÞÊ Óä£Ó\Ê / œ“Ãœ˜Ê ,iÕÌiÀÃÊ 7œ-ÆÊ ՏÞÊ Óä£Ó\Ê
              HIGHLIGHTS 2012                                         ˆLˆœ“iÌÀˆVÊ ˜>ÞÈÃÊ œvÊ >˜ViÀÊ ,iÃi>ÀV \Ê Ê >̈œ˜>Ê ˜ÌiÀ‡
                                                                      >˜VjÀœ«žiÃÉ >Ê-ÌÕ`Þ

              September
              Support provided to three new OncoStarter
              projects in this area
              s 2) 3#/,!)2% aims at implementing intervention
                Research on identifying and preventing Cancer in
                school environment
              s $%$%02/ has set out to adapt, implement and
                assess information and decision-support tools for
                prostate cancer screening with prostate-specific
                antigen testing
              s ).%'/ is studying factors contributing to inequa-
                lities in initial management of ovarian epithelial
                cancer in France between 2011 and 2014
              December
              Opening of the Hygée Center, a regional Cancer
              prevention center and public health platform in
              Saint-Étienne

     More info on www.canceropole-clara.com

10
SPOTLIGHT ON…
HUMAN AND SOCIAL SCIENCES
WORKING GROUPS LED BY INCa

                           Working group on
                           Quality of Worklife,
                           Quality of Care, Patient
                           Quality of Life
s Promoting and assisting the emergence of
  national research projects through open
  calls for projects in Human and Social
  Sciences, Environment and Public Health
s Helping determine research prospects
  in calls for projects in Human and Social
  Sciences, Environment and Public Health

INCa Inter-Cancéropôles Working group
on Inequality and Intervention Research
s Helping determine research prospects
  in calls for projects in Human and Social
  Sciences, Environment and Public Health
s Assisting the completion of national
  research projects resulting from calls
  for projects
Contact : Véronique REGNIER
­Þ}jiÊ i˜ÌiÀ]Ê->ˆ˜Ì‡̈i˜˜i®
                                                                    SPOTLIGHT ON…
                                                                    HYGÉE: REGIONAL CENTER FOR
First French Cancéropôle in                                         CANCER PREVENTION
scientific publications
                                                                                     The Hygée Center, the CLARA
1,36
                                                                                     regional public health platform,
           1,2
                                                                                     is housed in a 2500 square-meter
                                                                                     building near the Loire Cancerology
                                                                                     Institute and is divided into three
CLARA      IDF       NO       PACA      GE        GSO       GO                       operational divisions:
                    0,87                                            s Health education division focused on Cancer
                              0,82
                                        0,78                          prevention activities (primary, secondary and
                                                  0,66                tertiary) for the general public
                                                           0,57
                                                                    s Cancer treatment and Research education
€ÊÊ-«iVˆ>ˆâ>̈œ˜Ê ˆ˜`iÝÊ vœÀÊ >˜VjÀœ«žiÃÊ ˆ˜Ê «ÕLˆV>̈œ˜ÃÊ ˆ˜Ê     division
   ÜVˆ>ÊÃVˆi˜ViÃÊ
                                                                    s Public health Research division to raise regional
€ÊÊ6>ÕiÃÊ}Ài>ÌiÀÊÌ >˜Êœ˜iʈ˜`ˆV>ÌiÊÌ iÊ >˜VjÀœ«žiʈÃʓœÀiÊ
  ëiVˆ>ˆâi`ʈ˜ÊÌ iÊwi`ÊÌ >˜Ê>ÛiÀ>}iʈ˜ÊÀ>˜Vi                      awareness of Cancer and Cancer-related issues
                                                                    This Center represents an investment of €9M,
/ iÊ ,Ê Ìi>“Ê Ì >˜ŽÃÊ ÕViÌÌiÊ 8" Ê vœÀÊ iÀÊ                    provided by the French government, the Rhône-
Û>Õ>LiÊ ˆ˜«ÕÌÊ Ài}>À`ˆ˜}Ê Ì iÊ Õ“>˜Ê >˜`Ê ÃœVˆ>Ê                 Alpes Region, the Loire County, Saint-Étienne
ÃVˆi˜ViÃÊvœVÕÃÊ>Ài>Ê>˜`Ê«Àœ«œÃ>ÃÊvœÀÊiۜṎœ˜°                    Métropole and the Loire Cancerology Institute.

                                                                                                            Progress Report 2012

                                                                                                                                   11
Structuring of Research

           EMERGING THEMES

           ENVIRONMENTAL AND NUTRITIONAL FACTORS
           IN ONCOLOGY: PROMOTING INTERDISCIPLINARY
           RESEARCH THAT ACHIEVES NATIONAL VISIBILITY

           In response to the priorities of Cancer Plan II (measure 3),
           CLARA has incorporated an Environment, Nutrition
                                                                          KEY FIGURES 2012
           and Cancer focus area into its 2011-2014 program.
           Expanded from the thematic focus area Nutrition and
           Cancer developed between 2007 and 2010, it aims                > 4 OncoStarter projects
           to promote interdisciplinary Research in a field that           > 3 workshops (pesticides,
           has regional and national visibility and to contribute to        nanomaterials and nutrition)
           improving knowledge of risk factors:
                                                                          > 3 meetings of the INCa Working
           s Environmental (pesticides and nanomaterials)                   Group
           s Nutritional (metabolic mechanisms and
             preventive nutrition interventions)

                                                                          HIGHLIGHTS 2012
           SPOTLIGHT ON…
                                                                          February
           INCa WORKING GROUP                                             Launch of the OncoStarter project EXPO-NANO
           ON NUTRITION                                                   Coordinated by Jean-Michel VERGNON (CHU
                                                                          Saint-Étienne) and Jérémy POURCHEZ (Saint-
                                  Developing a National                   Étienne School of Mines), the goal of this
                                                                          project is to develop an indicator of exposure to
                                  Cancer Nutrition Research
                                                                          nanoparticles in order to monitor people who are
                                  Network (NACRe) and                     at occupational risk.
                                  CLARA national expertise in
                                                                          May
                                  Nutrition and Cancer to:                Workshop on Geographical Approaches
                                                                          to Evaluating Exposure to Pesticides at the
           s Promote and assist the emergence of national                 International Agency for Research on Cancer (IARC)
             research projects                                            and Léon Bérard Cancer Center, Lyon
           s Help determine research prospects                            July
                                                                          Scientific Forum of the Health-Environment
           Contact: Marie-Paule VASSON, ­>VՏÌÞʜvÊ                      Platform of Rhône-Alpes, EnvitéRA:
                                                                          Nanomaterials in the Environment and their Impact
           * >À“>VÞ]Ê1˜ˆÛiÀÈÌÞʜvÊÕÛiÀ}˜i®                              on the Ecosystem and Human Health
                                                                          September
                                                                          Launch of three new OncoStarter projects,
                                                                          including:
                                                                          s GEO3N on environmental exposure to dioxins
                                                                            and the risk of breast cancer
                                                                          s CASTA on breast cancer and obesity
                                                                          November
                                                                          INCa/National Cancer Nutrition Research
                                                                          Network (NACRe) Nutrition and Cancer Forum
                                                                          (Before, during, after)

     More info on www.canceropole-clara.com

12
SPOTLIGHT ON…
RESEARCH CHAIR OF EXCELLENCE
IN ENVIRONMENT, NUTRITION AND
CANCER
In 2010, with the support of the pharmaceutical           A public informational web portal on exposure to
company Merck Serono, CLARA awarded the                   risks related to the environment, workplace and
Chair of Excellence in “Environment, Nutrition and        personal behavior was also created. Its objective
Cancer” to Dr Béatrice FERVERS of the Cancer              is to provide scientifically sound public health
and Environment Unit of the Léon Bérard Cancer            information.
Center. During those three years, Dr FERVERS has
led two major research projects:                          www.cancer-environnement.fr

s Detecting occupational cancer, in collaboration
  with the Consultation Center for Professional
  Pathologies, the occupational health center
  of the Lyon Civil Hospitals. Aiming to improve
  patient education and overall patient care, this
  work received the label “Année des patients
  et de leurs droits” [year for patients and their
  rights] in 2011.
s Study of environmental and nutritional factors
  in breast cancer taking two complementary
  approaches:
  UÊÊ-ÌÕ`ÞʜvÊÌ iÊViÕ>À]ÊLˆœV i“ˆV>Ê>˜`Ê}i˜œ“ˆVÊ
    ˆ“«>VÌʜvÊV Àœ˜ˆVʏœÜ‡`œÃiÊiÝ«œÃÕÀiÊ̜ÊÃÕLÇ
    Ì>˜ViÃÊÌ >ÌÊ`ˆÃÀÕ«ÌÊi˜`œVÀˆ˜iÊv՘V̈œ˜
  UÊÊ,>˜`œ“ˆâi`Ê Vˆ˜ˆV>Ê ÃÌÕ`ÞÊ œvÊ Ì iÊ V >˜}ˆ˜}Ê
     “iÌ>LœˆVÊ>˜`ÊVÞ̜Žˆ˜iÊ«ÀœwiÃʈ˜Êܜ“i˜Ê`ˆ>‡
    }˜œÃi`Ê ÜˆÌ Ê LÀi>ÃÌÊ V>˜ViÀÊ «>À̈Vˆ«>̈˜}Ê ˆ˜Ê >Ê
    È݇“œ˜Ì ʘÕÌÀˆÌˆœ˜Ê«Àœ}À>“Ê­`ˆiÌÊ>˜`ÊiÝiÀVˆÃi®Ê
     Vœ˜Vœ“ˆÌ>˜ÌÊÜˆÌ ÊV>˜ViÀÊÌÀi>̓i˜Ì

                                                                                               Progress Report 2012

                                                                                                                      13
Structuring of Research

           TRANSVERSE ACTIONS: COMBINING THE
           PROACTIVE INTERREGIONAL ACTIONS OF RHÔNE-
           ALPES AUVERGNE WITH A NATIONAL APPROACH
           CONSISTENT WITH OTHER NETWORKS

           Eager to incorporate its actions into a national
           approach that includes interregional teams, CLARA
                                                                     KEY FIGURES 2012
           is actively participating in national INCa working
           groups and creating close ties with partner
           networks by embracing their initiatives.
                                                                     > 23% of funding for Hospital Clinical
                                                                       Research Program (PHRC)
                                                                       on Cancer projects in 2012 are
           VIRTUAL MICROSCOPY                                          CLARA projects
                                                                     > 160 participants in two inter-
           Inter-Cancéropôles Working group aiming to:                 Cancéropôles Bioinformatics
           s Share information and know-how for cross-                 workshops
             fertilization between Research-Clinical Care-
             Education approaches                                    > 16 meetings of national INCa
                                                                       Working groups
           s Issue recommendations that could become INCa
             recommendations                                         > 220 participants in the EPICLIN
           s Offer an international organization that works with       conference supported by CLARA
             business
           Contact: David MEYRONET ­ 1Êޜ˜®
                                                                   BIOINFORMATICS

                                                                                              Organizing top-tier inter-
                                                                                              Cancéropôles scientific
                                                                                              animation around the
                                                                   Bioinformatics platform of the Synergy Lyon Cancer
                                                                   Foundation and as part of the International Cancer
                                                                   Genome Consortium.
                                                                   The themes covered in 2012 in the half-yearly
                                                                   workshops were:
                                                                   s New generations of sequencing applied to
                                                                     Cancer transcriptomics
                                                                   s High-throughput epigenomics
                                                                   Contact: Gilles THOMAS ­1          ]Ê -ޘiÀ}ÞÊ ޜ˜Ê
                                                                    >˜ViÀʜ՘`>̈œ˜]Ê  ®

     More info on www.canceropole-clara.com

14
Photo : Romain ÉTIENNE / ITEM / Fondation
                                                                                                Synergie Lyon Cancer

CLINICAL RESEARCH                                          HIGHLIGHTS 2012

                         Putting the Clinical Cancer       April
                                                           4th Inter-Cancéropôles Bioinformatics
                         Research Support Platform
                                                           Workshop, Nice
                         of the Auvergne Rhône-
                         Alpes (PARCC-ARA) region at       May
                                                           19th Statistician Forum of the Centers for the
                         the center of the activities of   Fight Against Cancer and 6th Francophone
                         the INCa working group to:        Conference on Clinical Epidemiology (EPICLIN),
                                                           Lyon
s Increase the potential of clinical Cancer Research
                                                           September
  by helping investigators design, coordinate and
                                                           5th Inter-Cancéropôles Bioinformatics
  analyze their clinical studies                           Workshop, Lyon
s Improve INCa clinical trials registry data
s Guide actors involved in local clinical research on
  clinical trials
s Identify what determines the supply, demand,
  needs and conduct of Cancer clinical trials, espe-
  cially when they are associated with inequalities
Contact: David PEROL ­  ]Ê , ]Ê*,           ‡,®

                                                                                                     Progress Report 2012

                                                                                                                            15
Structuring of Research

           INTERNATIONAL: POSITIONING THE RHÔNE-ALPES AND
           AUVERGNE REGIONS AS EUROPEAN REFERENCE SITES
           IN THE FIGHT AGAINST CANCER

           Aware of the importance of expanding interregional
           Research beyond borders, CLARA is actively
                                                                KEY FIGURES 2012
           promoting international collaborations through
           two close partnerships:
                                                                > 20 European projects in progress,
           s With Spanish Cancer Research clusters                representing a budget of close to
             (Catalonia and Castilla y Léon)                      €100M
           s Between authorities in Shanghai and the Rhône-     > 2 strong collaborations:
             Alpes Region.                                        Shanghai and Spanish clusters
                                                                > 1 student (Master 2 (Bologna
                                                                  Process), then Ph.D. thesis) pursuing
             IN THEIR WORDS…                                      a joint University of Lyon/Shanghai
                                                                  University degree
             Encounter with Dr Véronique MAGUER-SATTA,
             ,"  / Ê«ÀœiVÌ

             º ,Ê >ÃÊÃÕ««œÀÌi`ÊÕÃÊ>ÌÊiÛiÀÞÊÃÌ>}iÊ
             œvÊ Ì ˆÃÊ ˆ˜ÌiÀ˜>̈œ˜>Ê «ÀœiVÌ]Ê Ü ˆV Ê
             ܜՏ`Ê ˜œÌÊ i݈ÃÌÊ ÜˆÌ œÕÌÊ ˆÌ°Ê ˜Ê >Ê ÜœÀ`]Ê
              ,Ê>œÜi`ÊÕÃÊÌœÊ >ÛiÊ>ÊۈȜ˜»

                                                                HIGHLIGHTS 2012
                                                                January
                                                                Biotecyl cluster’s visit to CLARA: Launch of a
                                                                French-Spanish, inter-cluster collaboration
                                                                March
                                                                Satellite event of the 7th Scientific Forum on
                                                                Nanomedicine and Oncology in Rhône-Alpes
                                                                Auvergne and Catalonia, in partnership with the
                                                                Biocat cluster
             6jÀœ˜ˆµÕiÊ1 ,‡-//Ê>˜`Ê iÀÊÌi>“
                                                                November
                                                                2nd Franco-Chinese Symposium on Cancer
             Read Dr Maguer-Satta’s complete comments at        Research, in partnership with the Rhône-Alpes
             www.canceropole-clara.com                          Region

     More info on www.canceropole-clara.com

16
SPOTLIGHT ON…                                             SPOTLIGHT ON…
COLLABORATION WITH SPANISH                                2ND FRANCO-CHINESE SYMPOSIUM ON
ONCOLOGY CLUSTERS                                         CANCER RESEARCH

In an effort to give a prominent European dimen-                                   Since 2011 and thanks to the
sion to the Rhône-Alpes Auvergne interregional                                     support of the Rhône-Alpes
Oncology cooperation, two firm partnerships were           Region, CLARA is leading an ambitious program of
forged in 2012 with the Biotecyl and Biocat Spanish       collaboration between academic teams in the region
clusters.                                                 and their counterparts in Shanghai.
                                                          The visit of a French delegation to Shanghai in July
               The collaboration with the Biotecyl
                                                          2011 resulted in the first collaboration, which focuses
               cluster (Salamanca, Castilla y Léon) is
                                                          on stem cells (breast and prostate cancer), between
               developing a joint work plan whose
                                                          Prof GAO (Med-X Renji Hospital, Stem Cell Research
               areas of Research relate to new
                                                          Center) and Dr MAGUER-SATTA (Cancer Research
therapeutic approaches, personalized medicine
                                                          Center of Lyon).
and biomarkers in sarcomas and leukemia. CLARA
invited the Spanish Research leaders to visit Lyon        To increase momentum, a delegation of Chinese
in January to prepare an application for an               researchers and institutional representatives was
Interreg program.                                         received in Lyon in November 2012. The goal was to
                                                          improve mutual understanding of the two countries’
             As part of the 7th CLARA Scientific
                                                          approaches to the management of Cancer Research
             Forum, a satellite event was organized
                                                          and care, present the results of the first joint projects
             with the Biocat cluster (Catalonia)
                                                          and initiate and strengthen collaborative efforts.
             on Nanomedicine and Oncology
in Rhône-Alpes Auvergne and Catalonia. Ten                Several partnerships are now being set up.
researchers, clinicians and CEOs were invited to
share their activities with regional actors in order to
develop partnerships.

                                                                                                     Progress Report 2012

                                                                                                                            17
Supporting Research Projects

          FOSTERING THE EMERGENCE OF PROJECTS

           MOBILITY: BUILDING TOMORROW’S TALENT

                                           Mobility for young
                                           researchers is a source   EXAMPLES OF 2012 PROJECTS
                                           of acquiring new tech-
                                           niques and knowledge      > Étude des instabilités génétiques des dysplasies
           and promotes the emergence and strengthening of             pré-cancéreuses tubo-ovariennes chez les
           collaborative projects. For this reason, CLARA set up       patientes à risque génétique (Jean Perrin
                                                                       Cancer Center, Clermont-Ferrand Î
           a program in 2011 focusing on mobility.                     Montreal University Hospital, Canada)
           Intended for young researchers in Rhône-Alpes             > Étude de la Caséine Kinase 2 et de ses
           Auvergne involved in Oncology projects requiring            inhibiteurs ; cytotoxicité vis-à-vis de cellules
                                                                       tumorales pancréatiques (Claude Bernard Lyon
           regional, national or international travel lasting
                                                                       1 University Î CEA of Grenoble)
           between one and three weeks, the CLARA Mobility
           program can assist with funding up to €2,500.             > Impact des expositions environnementales
                                                                       prénatales sur l’incidence du cancer du testicule
                                                                       (IARC Î Danish Cancer Society, Karolinska
                                                                       Institute, Sweden)
                                                                     / iÊVœ“«iÌiʏˆÃÌʜvÊ«ÀœiVÌÃÊ>««i>ÀÃʈ˜ÊÌ iÊ
                                                                     >««i˜`ˆViÃÊ­ÃiiÊ«°ÊÓn®

                                                                     KEY FIGURES 2012

                                                                     > €20,000 allocated
                                                                     > 8 grants for Mobility

             Geographic Origin of Selected                           Destination of Selected Mobility Projects
             Mobility Projects
                                                                         38%
                                                                      International

                                                       13%                                                       37%
                                                  Clermont-Ferrand                                               Within
                                                                                                                 CLARA
                                                                                                                 Perimeter

                                                     87%              25%
                                                      Lyon           National

     More info on www.canceropole-clara.com

18
KEY FIGURES 2012
FOSTERING THE EMERGENCE OF PROJECTS
                                                       > €405,000 allllocated
ONCOSTARTER:                                           > 8 projects chosen
SUPPORTING THE                                           s 3 projects in Translational Research
EMERGENCE OF                                             s 5 projects in Environment,
                                                           Nutrition, and Human and Social
INNOVATIVE PROJECTS                                        Sciences

                             Since 2011, thanks
                             to its unique
                             position allowing
                             it to speed up
                                                       EXAMPLES OF 2012 PROJECTS
                             project      deve-
                                                       Translational Research
lopment to maximize chances of receiving later
                                                       > Potentialisation des traitements des cancers du
funding, OncoStarter complements traditional              pancréas
project development systems as well as, among          > Nouveau marqueur pronostic et prédictif du
others, ,Ê *ÀœœvÊ œvÊ œ˜Vi«ÌÊ and INCa calls           cancer du sein ER+
for projects.                                          > Développement de nanoparticules fluores-
                                                          centes pour la détection des lésions tumorales
In addition to financial assistance allocated              colorectales
to solidify scientific data, teams can receive
                                                       Emerging Themes
personalized coaching to raise the level of quality
                                                       > Représentations et prévention des cancers
of their projects (extension of partnerships, market     en milieu scolaire
research, consideration of regulatory issues, etc.).
                                                       > Évaluation d’outils d’information et d’aide
Open to all Translational Research projects as well      à la décision dans le dépistage du cancer de
                                                         la prostate
as those that fall within emerging themes identified
                                                       > Facteurs d’inégalités de la prise en charge
by CLARA (Assessment, Perception of Risks                initiale des cancers épithéliaux ovariens
and Cancer Prevention, Environment, Nutrition          > Vers un indicateur d’exposition aux nanoparticules
and Cancer), it promotes the development of            > Expositions environnementales aux dioxines
multidisciplinary approaches.                            et risque de cancer du sein

                                                       / iÊVœ“«iÌiʏˆÃÌʜvÊ«ÀœiVÌÃÊ>««i>ÀÃʈ˜ÊÌ iÊ>««i˜‡
                                                       `ˆViÃÊ­ÃiiÊ«°ÊÓn®
  In 2012, top priority was given to supporting
  projects on emerging themes: Environment,
  Nutrition, Human and Social Sciences
                                                       Balanced location-based projects

                                                                1%
                                                           Grenoble
     30%                                                                                          3%
                                                                                              Saint-Étienne
  Translational
    Research

                                           70%
                                          Emerging       5%                                      1%
                                                         Lyon                              Clermont-Ferrand
                                           Themes

                                                                                                 Progress Report 2012

                                                                                                                        19
Supporting Research Projects

           CLARA PROOF OF CONCEPT: A KEY STEP IN REACHING
           CLINICAL CARE FASTER

           Since 2005, CLARA has been running a unique and
           powerful program for exploitation of research results:
                                                                     KEY FIGURES 2012
           the *ÀœœvʜvÊ œ˜Vi«ÌÊ«Àœ}À>“°Ê
           Through financial support and assistance to academic       > 1 robotic surgical device on the
           and clinical teams in Rhône-Alpes Auvergne, this            market
           program makes it easier to develop preclinical
           projects and clinical studies on high-potential product   > 5 projects in clinical development
           candidates (drugs and devices) and generate industrial    > 6 preclinical assessments
           property to support them.                                   performed
                                                                     > 32 projects supported, including
                                                                       15 in progress and 5 in post-project
                                                                       follow-up**
                                                                     > €37,3 M overall budget
                                                                       (€25,1M invested by interregional
                                                                       business partners and €12,2M by
                                                                       local authorities and ERDF)
                                                                     > More than 70 partners, including
                                                                       7 clinical centers
                                                                     > 41 scientific publications*
                                                                     > 43 scientific press releases*
                                                                     > 25 patent applications*
                                                                     * >Ãi`ʜ˜Ê`>Ì>Ê>Û>ˆ>Liʜ˜Ê iVi“LiÀÊΣ]ÊÓä£Ó
                                                                     **Ê*ÀœiVÌÃÊ>ÀiÊ`iÃVÀˆLi`ʈ˜ÊÌ iÊ>««i˜`ˆÝÊ­ÃiiÊ«°Êә®

           In partnership with a company working within
           CLARA’s scope of activities that is conducting and
           committed to exploiting the research results in the
           long run, the program focuses on local economic
           growth and contributes to promoting innovative
           therapeutic and diagnostic solutions that directly
           benefit patients.

     More info on www.canceropole-clara.com

20
HIGHLIGHTS 2012

January
Synfrizz launches its phase 1 clinical trial first in
man/first in class to develop a new treatment for
synovial sarcoma. Based on an innovative treatment
combining anti-FZD10 antibody with radiation therapy, it
is the first targeted treatment in the world for this type of
Cancer. The trial will take place for 24 months and involve
21 sarcoma patients in three French Cancer centers.
May
Creation of Anastom Surgical as part of the UroLink
project. Led by Arnold FERLIN, the company Anastom               A vast field of application of proofs of concept
Surgical is the business partner in the UroLink project          targeted since 2005
whose goal is to develop automated urethrovesical
anastomosis for prostate cancer. Spawned from the                                  12%
technology incubator CREALYS, Anastom Surgical is the                           Radiotherapy
2012 laureate of the 13th Tremplin Entreprise [Business                                                                28%
Springboard] co-organized by the French Senate and ESEC.                                                         Immonotherapy,
                                                                     12%                                           Biomolecule
June                                                             Chimiotherapy
The Enki-HEH project starts clinical trials at the
Lyon Civil Hospitals to test a new tumor resection                  3%
technique that uses a pulsed jet of water.                         Cellular
                                                                   Therapy
July
A study of high-intensity focused ultrasound                           9%
                                                                 Medical Imaging
(HIFU) begins the phase 2b clinical trial stage for                                                                    24%
                                                                                                                Medical / Surgical
the treatment of hepatic metastases. Launched in
                                                                                   12%                              Device
2011, phase 2a clinical trials were approved in February                      Diagnostic Tool
2012 by a committee of experts. The approvals for
moving to phase 2b by the institutional review board
(CPP) and French Agency for Health Product Safety
(ANSM) were granted in summer 2012. The first three
patients were enrolled in September 2012.                        Targeted pathologies within the Proof of
The procedures for obtaining CE marking were                     Concept program since 2005
initiated in December 2012.                                      3 major indications : breast (17%), liver (12%) and
August                                                           brain tumors (12%)
GeniusVac-Mel4 requests approval of a phase
                                                                                          7%
1 clinical trial. The objective of the project is to develop                          Multiple          2%
an innovative drug treatment (cell therapy) for melanoma.                     7%                        ENT
After receiving a positive response from CPP in October                Lymphoma                                      17%
                                                                                                                     Breast
2012, feedback from ANSM is expected in 2013.                           7%
                                                                    Sarcoma
September
Reception of nine letters of intent as part of the                     3%
8th CLARA Proof of Concept call for projects (six                  Stomach
                                                                                                                              12%
                                                                                                                              Liver
applications assessed)                                                3%
                                                               Oesophagus
November
HepatoFluo received approval to start its phase 1                        5%
                                                                   Colorectal
clinical trial. Based on Fluobeam™ technology from                                                                      12%
                                                                              3%                                        Brain
the company Fluoptics, the objective of the HepatoFluo                   Kidney

project is to assess the feasibility and effectiveness of a                   5%                              10%
                                                                         Prostate                             Lung
fluorescent marker in improving surgical procedures for                                           7%
                                                                                                 Skin
hepatic metastases and primary liver cancer. Patient en-
rolment will begin in January 2013. The device received
CE marking in December 2012.
                                                               / iÊ ,Ê Ìi>“Ê Ì >˜ŽÃÊ >Ê Ì iÊ iÝ«iÀÌÃÊ “œLˆˆâi`Ê ˆ˜Ê Ì iÊ
/ iÊVœ“«iÌiʏˆÃÌʜvÊ«ÀœiVÌÃÊ>««i>ÀÃʈ˜ÊÌ iÊ>««i˜`ˆVið       ÃiiV̈œ˜Ê >˜`Ê ˆ˜Ê Ì iÊ vœœÜ‡Õ«Ê œvÊ «ÀœiVÌÃ]Ê “œÃÌÊ ˜œÌ>LÞÊ
                                                               i>˜‡>VµÕiÃÊ<  ,Ê>˜`ʈV iÊ"6 /°

                                                                                                                      Progress Report 2012

                                                                                                                                             21
Supporting Research Projects

           MAJOR INTERREGIONAL PROJECTS: ENHANCING THE
           REPUTATION OF THE TERRITORY IN ONCOLOGY

           Emphasizing the importance of making sure that            ELI
           interregional research teams join forces in innovative    EUROPEAN LYMPHOMA INSTITUTE
           and competitive projects that address national
           Cancer Research priorities and favorably position
                                                                                       Uniting the most prominent
           interregional teams in Europe, CLARA and local
                                                                                       lymphoma specialists in Europe in
           authorities have partnered since 2009 to implement
                                                                                       an institute dedicated to Research,
           a strategy of providing maximum support to
                                                                     training and education, ELI’s goal is to determine a
           development projects.
                                                                     strategy, therapeutic and diagnostic standards and
           Sponsor of leading cooperative groups, such as            facilitate basic and clinical Research in Europe.
           the European Lymphoma Institute (ELI) and World
                                                                     Using this one-of-a-kind collaborative operating
           Sarcoma Network (WSN), CLARA decided this year
                                                                     model, ELI wants to advance lymphoma Research
           to fund a chair of excellence in Translational Research
                                                                     to offer all patients equal access to the best care.
           in Oncology in Grenoble.
                                                                     Contact: Bertrand COIFFIER ­ 1Êޜ˜®

           CHAIR OF EXCELLENCE IN
           TRANSLATIONAL RESEARCH IN
           ONCOLOGY IN GRENOBLE                                        Lymphoma: 6th Highest Incidence of Cancer in
                                                                       the World

           In 2012, CLARA, CHU Grenoble, Joseph Fourier                                               3%
                                                                                      3%              Kidney
           University, Isère County, Grenoble Alpes Métropole                      Bladder
                                                                                                           3%
           and the City of Grenoble co-funded a chair of                              3%                   Pancreas
                                                                              Lymphoma
           excellence in Translational Research.
                                                                                      3%                                     30%
                                                                         Lip, Oral Cavity,                                   Others
           Associated with the creation of a laboratory and                      Pharynx
           dedicated team at the Albert Bonniot Institute,                    11%
                                                                               Lung
           this chair of excellence aims to mobilize the
           driving forces in Grenoble to collaborate with
           pharmaceutical companies to develop innovative
                                                                                   11%
           applications.                                                 Colon-Rectum
                                                                                                                       19%
           Contact: Christian BRAMBILLA ­LiÀÌÊ œ˜˜ˆœÌÊ                                     15%                       Prostate
                                                                                             Breast
           ˜Ã̈ÌÕÌi]ÊÀi˜œLi®
                                                                      Source :    >Ê-ˆÌÕ>̈œ˜Ê`ÕÊ >˜ViÀÊi˜ÊÀ>˜ViÊi˜ÊÓä£Ó

     More info on www.canceropole-clara.com

22
You can also read